

Title (en)

EXPRESSIONANALYSIS OF SPECIFIC NUCLEIC ACIDS AND POLYPEPTIDES USEFUL IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Title (de)

EXPRESSSIONSANALYSE SPEZIFISCHER NUKLEINSÄUREN UND POLYPEPTIDE ZUR VERWENDUNG IN DER DIAGNOSE UND DER BEHANDLUNG VON PROSTATA KREBS

Title (fr)

ANALYSE DE L'EXPRESSION D'ACIDES NUCLEIQUES ET DE POLYPEPTIDES SPECIFIQUES UTILES POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE

Publication

EP 1117836 A2 20010725 (EN)

Application

EP 99952976 A 19990930

Priority

- US 9922535 W 19990930
- US 16415998 A 19980930
- US 16375998 A 19980930

Abstract (en)

[origin: WO0018961A2] The invention is based in part on the discovery of a number of genes (HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19) which are androgen-inducible in androgen-dependent prostate cancer (e.g., LNCaP cells) and constitutively expressed in androgen-independent prostate cancer cells (e.g., LN3 LNCaP cells). Because androgen is required for growth and survival of androgen-dependent prostate cancer cells, HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19 are therapeutic targets. An agent which decreases the expression or activity of HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, or HRPCa 19 may slow or arrest the growth of prostate cancer cells or may kill prostate cancer cells. Moreover, because the genes of the invention are constitutively expressed by androgen-independent prostate cancer cells, they can be used to identify agents useful for the treatment of androgen-dependent and androgen-independent prostate cancer.

IPC 1-7

C12Q 1/68; C07K 14/47

IPC 8 full level

G01N 33/50 (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C12N 15/09** (2006.01); **C12Q 1/02** (2006.01);
C12Q 1/68 (2006.01); **G01N 33/15** (2006.01); **G01N 33/53** (2006.01); **G01N 37/00** (2006.01); **A61K 38/00** (2006.01); **C12R 1/91** (2006.01)

CPC (source: EP)

A61P 35/00 (2017.12); **C12Q 1/6809** (2013.01); **C12Q 1/6886** (2013.01); **A61K 38/00** (2013.01); **C12Q 2600/106** (2013.01);
C12Q 2600/136 (2013.01)

Citation (search report)

See references of WO 0018961A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0018961 A2 20000406; WO 0018961 A3 20010308; AU 6502199 A 20000417; CA 2344550 A1 20000406; EP 1117836 A2 20010725;
JP 2002531061 A 20020924

DOCDB simple family (application)

US 9922535 W 19990930; AU 6502199 A 19990930; CA 2344550 A 19990930; EP 99952976 A 19990930; JP 2000572408 A 19990930